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Background. Rotavirus vaccination reduces childhood hospitalization in Africa, but cost-effectiveness has not been determined
using real-world effectiveness and costing data. We sought to determine monovalent rotavirus vaccine cost-effectiveness in Malawi,
one of Africa’s poorest countries and the ﬁrst Gavi-eligible country to report disease reduction following introduction in 2012.
Methods. This was a prospective cohort study of children with acute gastroenteritis at a rural primary health center, a rural ﬁrst
referral–level hospital and an urban regional referral hospital in Malawi. For each participant we itemized household costs of illness
and direct medical expenditures incurred. We also collected Ministry of Health vaccine implementation costs. Using a standard tool
(TRIVAC), we derived cost-effectiveness.
Results. Between 1 January 2013 and 21 November 2014, we recruited 530 children aged <5 years with gastroenteritis. Costs did
not differ by rotavirus test result, but were signiﬁcantly higher for admitted children and those with increased severity on Vesikari
scale. Adding rotavirus vaccine to the national schedule costs Malawi $0.42 per dose in system costs. Vaccine copayment is an ad-
ditional $0.20. Over 20 years, the vaccine program will avert 1 026 000 cases of rotavirus gastroenteritis, 78 000 inpatient admissions,
4300 deaths, and 136 000 disability-adjusted-life-years (DALYs). For this year’s birth cohort, it will avert 54 000 cases of rotavirus and
281 deaths in children aged <5 years. The program will cost $10.5 million and save $8.0 million in averted healthcare costs. Societal
cost per DALY averted was $10, and the cost per rotavirus case averted was $1.
Conclusions. Gastroenteritis causes substantial economic burden toMalawi. The rotavirus vaccine program is highly cost-effective.
Together with the demonstrated impact of rotavirus vaccine in reducing population hospitalization burden, its cost-effectiveness makes
a strong argument for widespread utilization in other low-income, high-burden settings.
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Rotavirus gastroenteritis is a leading cause of illness and death in
African children, accounting for >197 000 deaths annually, just
over half of the global rotavirus mortality burden [1, 2]. Since
2012, with Gavi, the Vaccine Alliance (hereafter “Gavi”) support,
25 African countries have introduced rotavirus vaccine into their
childhood immunization programs. New vaccines are costly to
the health system, and the expenditure should be justiﬁed on
epidemiological and ﬁscal grounds as investment in vaccine pro-
grams necessarily denies funds from competing health priorities.
Additionally, as Gavi-supported countries are required to make co-
payments for vaccines, knowing these vaccines are cost-effective is
important for budgetary planning and negotiating procurement
costs. Cost-effectiveness is evaluated in terms of gross domestic
product (GDP) and thus is context dependent, both with respect
to program and treatment costs but also with respect to local vac-
cine effectiveness. According to World Health Organization
(WHO) criteria, cost per disability-adjusted life-year (DALY) [3]
ratios <3 times the per-capita GDP are considered cost-effective,
whereas those less than per-capita GDP are considered highly
cost-effective [4]. (DALY measures the population loss of years
of life lived in perfect health.) Estimates from middle- or high-in-
come settings are therefore not applicable to low-income countries.
Malawi, a low-income country in southern Africa with
under-5 mortality of 71 per 1000 live births and GDP per capita
of $253 [5], was one of the ﬁrst countries on the continent to
introduce monovalent rotavirus vaccine in 2012. The govern-
ment of Malawi is the main healthcare provider in the country
and healthcare is free at government facilities, although families
often incur considerable ancillary costs and there is no national
health insurance scheme. We recently described monovalent
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rotavirus vaccine effectiveness against severe acute rotavirus
gastroenteritis of 64% (95% conﬁdence interval, 24%–83%) in
routine use in Malawi [6]. Previous cost-effectiveness studies
fromMalawi and elsewhere in Africa conducted prior to vaccine
introduction were based on modeled (top-down) estimates of
cost rather than empirically observed (ground-up) actual ex-
penditures [7–9]. We now report results from a comprehensive
individual patient costing cohort study using actual ongoing
costs incurred by the health system and by households to deter-
mine, from a government and from a societal perspective, rota-
virus vaccine cost-effectiveness following introduction.
METHODS
Study Sites and Design
Between 1 January 2013 and 21 November 2014, we conducted a
prospective cohort study of children <5 years of age resident with-
in the study site catchment areas presenting with acute gastroen-
teritis in northern and southern Malawi. The northern rural site
was located in Chilumba Rural Hospital campus, Karonga, on
which site are colocated an “under-5” primary health center pro-
viding childhood outpatient services and, adjacently housed, a
ﬁrst-referral-level inpatient facility. Both service the population
within a demographic surveillance site in Chilumba that has
been described previously [10, 11]. The southern urban site was
at Queen Elizabeth Central Hospital, Blantyre, which is the tertiary
referral center for Malawi’s south and serves as a district hospital
for the city of Blantyre (population 1.3 million). All sites are gov-
ernment facilities providing free healthcare. At these sites, with pa-
rental written consent, we recruited both outpatient and admitted
children. We excluded children admitted to another hospital >24
hours who then subsequently transferred to study facilities, chil-
dren re-presenting for the same illness within 14 days, and children
with known oncological or congenital immunodeﬁciency other
than human immunodeﬁciency virus infection. Demographic
and clinical data were collected at enrollment (Table 1) and disease
severity on admission was measured by Vesikari score, with severe
disease deﬁned as a score >10. Stool specimens were tested for ro-
tavirus using enzyme immunoassay (Rotaclone, Meridian Bio-
science, Cincinnati, Ohio). We followed up children surviving to
facility discharge with a home visit after 6 weeks to obtain all ill-
ness-related costs incurred after discharge. Initial training of inter-
viewers was exhaustive and included role-play scenarios as well as
peer review to ensure consistency in data recording and interpre-
tation of parental answers regarding income and expenditures.
Data on Cost of Illness
Using a standard case report form, we undertook detailed item-
ized individual patient–level determination of actual expenditures
related to the current illness. From a household perspective, we
collected by parental interview self-reported recall of all illness-
related expenditures from symptom onset to convalescence at
home after discharge, including transport costs to and from health
facilities, loss of income and other opportunity costs, costs of
formal and informal healthcare seeking (including household ex-
penditure on consultations, diagnostics, and therapeutics in com-
munity healthcare facilities, traditional healers, or other informal
care), and costs related to accommodation and food for visiting
family members during admission of the index child and any di-
rect medical costs. We did not include long-run costs arising from
any disability related to the acute illness episode.
From a government healthcare provider perspective, we col-
lected actual costs incurred in our cohort (Table 2). From the
medical record we obtained individual-level drugs dispensed
and laboratory or radiological investigations performed. Use
of clinical consumables (intravenous cannula, stationery, etc)
was difﬁcult to account for per child and thus was not included,
although our experience in these facilities suggests these costs
are likely to be minimal. Drug consumption was costed based
on actual procurement purchase costs obtained from the pur-
chasing ofﬁcer. Laboratory investigations were costed on basis
of actual charge incurred by the respective facilities for each spe-
ciﬁc investigation performed; this charge was inclusive of labo-
ratory consumables, staff time, etc. Costs for each cadre of staff
were calculated by multiplying actual salaries (including oncosts
such as medical beneﬁts scheme contributions, study leave,
other allowances, etc) of staff in observed ward attendance di-
vided by ward occupancy and multiplied by individual patient
length of stay. We did not include staff time not spent on direct
patient care (eg, in-service training). Hotel costs (ie, kitchen,
laundry, sanitation, security, amenities, and transportation)
were based on actual hospital expenditures per bed multiplied
by individual length of stay. Hospital administration costs, cap-
ital costs, or physical asset depreciation were not included.
Household costs included all illness-related expenditures that
were incurred at each health facility attended, such as direct med-
ical costs (consultation fees, drug cost, diagnostic test cost), trans-
port cost, and any other costs relating to illness as reported by the
respondent. We collected costs of accommodation, food, and any
other items (soap, cup, etc) for all participants, although only in-
patients reported such costs. Opportunity costs (eg, lost income)
were included for all participants regardless of which facility they
attended. The combination of healthcare costs and household
costs over all projected birth cohorts constitute the total societal
cost. All costs were collected in 2014 Malawi kwacha, which were
converted to US dollars based on the Reserve Bank of Malawi
midmarket exchange rate as of 15 July 2014 (Table 2).
Data on Vaccine Program Cost
Ongoing rotavirus vaccine program cost projections were provid-
ed by the 2012–2016 comprehensive Expanded Programme on
Immunization (EPI) multiyear plan [12].Cost categories included
staff training, community sensitization, surveillance, manage-
ment, transport, maintenance, and capital costs (such as cold stor-
age and transport). We did not include depreciation of capital
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costs. Personnel costs were excluded because no additional EPI
staff were employed with the introduction of rotavirus vaccine,
and all work was absorbed by existing staff. We used the mean
expenditure over a 5-year period to represent the average annual
cost we would expect over the life of the program. These costs
were divided by total doses required by the birth cohort, and
the cost share was allocated to rotavirus on a per-antigen-dose
basis to obtain a system cost per dose as 2014 Malawi kwacha.
Our calculations indicate that the addition of rotavirus vaccine
to the routine EPI schedule increases system costs by $0.42 per
dose. Malawi’s copayment is $0.20 [13], with the remainder of
the $2.50 dose cost being borne by Gavi. As sensitivity analysis,
we modeled Malawi taking on the full cost of $2.50 from both
2023 and 2028, respectively 10 and 15 years after introduction.
Data on Disease Burden and Vaccine Effectiveness
Disease burden estimates were based on our observed incidence
in Malawi and other published burden estimates from Africa
[14, 15];we assumed no changes in quality or availability of clin-
ical care or of population nutrition over time (Table 3). Vaccine
coverage and timeliness were those empirically observed in our
surveillance program (Table 3) [6]. We used our recently pub-
lished estimate of vaccine effectiveness against severe disease in
Malawi [6], but input lower effectiveness against mild disease
Table 1. Cohort Demographics
Characteristic
Urban Rural
Inpatient (n = 282) Outpatient (n = 118) Total (n = 400) Inpatient (n = 22) Outpatient (n = 108) Total (N = 130)
Age
0–11 mo 151 (54) 42 (36) 193 (48) 11 (50) 53 (49) 64 (49)
12–23 mo 105 (37) 51 (43) 156 (39) 5 (23) 26 (24) 31 (24)
24–59 mo 24 (9) 17 (14) 41 (10) 4 (18) 26 (24) 30 (23)
Mean (SD), mo 13.6 (8.0) 17.9 (13.0) 14.8 (9.8) 16.2 (14.2) 15.9 (11.4) 15.9 (11.8)
Male sex 168 (60.0) 63 (53) 231 (58) 9 (41) 62 (57) 71 (55)
Persons in household, median (IQR) 5 (4–6) 4 (3–5) 5 (3.5–6) 6 (4–7) 6 (5–7) 6 (4–7)
Transport to facility
Walk 15 (5) 17 (14) 32 (8) 10 (46) 59 (55) 69 (53)
Bicycle 1 (0.4) 0 1 (0.3) 10 (46) 36 (33) 46 (35)
Car 19 (7) 1 (1) 20 (5) 0 3 (3) 3 (2)
Minibus 214 (76) 84 (71) 298 (75) 0 0 0
Other 18 (6) 36 (31) 54 (14) 2 (9) 10 (9) 12 (9)
Water source
Piped to house 38 (14) 23 (20) 61 (15) 2 (9) 14 (13) 16 (12)
Communal piped tap 187 (66) 86 (73) 273 (68) 3 (14) 16 (15) 19 (15)
Borehole 35 (12) 5 (4) 40 (10) 7 (32) 31 (29) 38 (29)
Protected well 3 (1) 0 3 (1) 0 5 (5) 5 (4)
Open well 11 (4) 1 (1) 12 (3) 4 (18) 2 (2) 6 (5)
Open lake/stream 0 0 0 0 1 (1) 1 (1)
Toilet facilities
Flush toilet 12 (4) 6 (5) 18 (5) 0 0 0
Improved latrine 0 1 (1) 1 (0.3) 0 0 0
Pit latrine 261 (93) 106 (90) 367 (92) 16 (73) 58 (54) 74 (57)
Open 2 (1) 1 (1) 3 (1) 6 (27) 50 (46) 56 (43)
Handwashing facilities available 85 (30) 71 (60) 156 (39) 4 (18) 23 (21) 27 (21)
Caregiver
Mother 274 (97) 118 (100) 392 (98) 20 (91) 102 (94) 122 (94)
Education of caregiver
Tertiary 17 (6) 3 (3) 20 (5) 0 1 (1) 1 (1)
Secondary 113 (40) 64 (54) 177 (44) 5 (23) 28 (26) 33 (25)
Primary 122 (43) 46 (39) 168 (42) 15 (68) 76 (70) 91 (70)
None 6 (2) 1 (1) 7 (2) 0 0 0
Unknown 15 (5) 3 (3) 18 (5) 0 0 0
Profession of caregiver
Housework/child care 157 (56) 68 (58) 225 (56) 12 (55) 41 (38) 53 (41)
Farming 7 (3) 2 (2) 9 (2) 6 (27) 4 (4) 10 (8)
Small business/self-employed 75 (27) 30 (25) 105 (26) 2 (9) 2 (2) 4 (3)
Data are presented as No. (%) unless otherwise specified.
Abbreviations: IQR, interquartile range; SD, standard deviation.
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based on published estimates and an unpublished systematic re-
view of effectiveness studies [14] (Dan Hungerford, personal
communication). We used published case fatality estimates
from regional countries, and these were consistently within
the error margin of our own measured fatality rate (Table 3)
[2, 11, 16]. Because evidence indicates that monovalent rotavirus
vaccine provides heterotypic (cross-genotype) protection [20],
we assumed no impact on effectiveness over time from genotype
replacement in primary analysis, but allowed for this in sensitiv-
ity analysis. We assumed waning immunity beyond the ﬁrst year
of life, but modeled unchanging ongoing protective immunity
in sensitivity analysis [18, 19]. Disability weighting for DALY
calculations was based on published estimates (Table 3) [17].
Statistical Analysis
Sample size was speciﬁcally calculated for this costing study.
Taking a healthcare provider perspective, using predeﬁned
precision about a continuous cost estimate, a sample size of
88 provided a diarrheal illness cost estimate with a margin of
error of ≤10%, assuming a coefﬁcient of variation of 0.5 and
at least 1000 children with diarrhea presenting to our study
site annually [21–23]. Larger samples provide more precise
cost estimates. Mean (therefore total) costs and 95% conﬁdence
bounds were reported for households and healthcare provider
costs [24]. These analyses were done using Stata software,
version 13.1 (StataCorp, College Station, Texas). Vaccine cost-
effectiveness was calculated using TRIVAC 2.0 (Pan-American
Health Organization), extensive details of which have been pub-
lished previously [14, 25]. In brief, TRIVAC uses input demo-
graphic and disease burden data, vaccine cost, and coverage
and effectiveness estimates, as well as user input healthcare uti-
lization and costs to determine incremental cost-effectiveness
over 20 stacked under-5 cohorts to derive years of life lost and
cost per DALY gained for each cohort’s life expectancy at birth
Table 2. Input Parameters for Estimating Health Service Costs, and Per-Visit Costs by Admission Status and Disease Severity
Sector in Which Cost Incurred No. Estimate 95% CI No. Estimate 95% CI Rank-Sum P Value
Government cost overall Outpatient Inpatient
Public health center 108 $8.02 $7.47–$8.57 22 $55.04 $43.15–$66.93 <.001
Public tertiary referral hospital 118 $7.15 $6.41–$7.90 282 $47.16 $40.65–$53.67 <.001
Government cost overall Nonsevere disease Severe disease
Public health center 128 $15.50 $11.92–$19.08 2 $46.34a $0–$357.84 .05
Public tertiary referral hospital 197 $26.22 $17.86–$34.57 207 $43.59 $38.54–$48.64 <.001
Government cost for outpatient visit
Public health center 108 $8.02 $7.47–$8.57 0b . . . . . . .12c
Public tertiary referral hospital 116 $7.02 $6.32–$7.72 2 $14.85 $0–$120.79 .08
Government cost for inpatient admission
Public rural hospital 20 $55.91 $43.32–$68.49 2 $46.34 $0–$357.84 .65d
Public tertiary referral hospital 77 $55.90 $36.07–$75.73 205 $43.87 $38.79–$48.96 .25d
Household cost overall Outpatient Inpatient
Public health centere 108 $0.49 $0.30–$0.68 22 $9.43 $4.96–$13.89 <.001
Public tertiary referral hospital 118 $5.80 $3.93–$7.68 282 $10.76 $9.38–$12.13 <.001
Household cost overall Nonsevere disease Severe disease
Public health center 128 $1.81 $0.92–$2.71 2 $14.23 $0–$100.57 .015
Public tertiary referral hospital 197 $7.69 $6.17–$9.21 207 $10.94 $9.29–$12.59 <.001
Household cost for outpatient visit
Public health centere 108 $0.49 $0.30–$0.68 0 . . . . . . .56c
Public tertiary referral hospital 116 $5.80 $3.93–$7.68 2 $6.82 $0–$21.26 .23
Household cost for inpatient admission
Public rural hospital 20 $8.95 $4.16–$13.73 2 $14.23 $0–$100.57 .25
Public tertiary referral hospital 77 $10.16 $7.75–$12.56 205 $10.98 $9.31–$12.65 .38
Other household costs
Private pharmacy $0.23 $0.09–$0.36 $0.28 $0.10–$0.46
Private clinic $0.04 $0.01–$0.07 $0.13 $0.00–$0.27
All costs are in 2014 US dollars.
Abbreviation: CI, confidence interval (estimate ± 1.96 × standard error).
a All severe cases in rural setting were admitted to the rural hospital on site (these costs were not entered twice in the cost-effectiveness model).
b Cases with severe disease were admitted after first being seen in outpatient clinic. Subsequent costs of severe disease when admitted were counted under inpatient admission and not
outpatient visit. Outpatient visits occurred at public health center and at the outpatient department of the public referral hospital. Inpatient admissions occurred at the public rural hospital and the
public referral hospital.
c Linear regression of cost vs Vesikari score for those with score <10.
d Nonsignificant but higher cost point estimate in nonsevere group, possibly explained by admission indicated by other comorbidity rather than gastroenteritis severity itself.
e Total outpatient costs, including costs of healthcare sought before arrival at recruitment facility.
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[14].We used the projected annual number of live births and age-
speciﬁc population projections for Malawi from United Nations
Population Division projections 2012 to determine the number
of live births in 2013 as 651 684 [26]. We chose to model costs
and beneﬁts over a 20-year horizon to assist policy makers in
assessing the long-term implications of their decisions. Future
costs and beneﬁts were discounted to 2014 levels at 3%.
Sensitivity Analyses
We conducted univariate sensitivity analysis on variables that
impacted our TRIVAC model results most dramatically
Table 3. Input Parameters for Estimating Disease Burden, Vaccine Coverage, Timeliness, and Effectiveness
Parameter Estimate Source(s)
Annual incidence per 100 000 aged 1–59 mo
Rotavirus (nonsevere) cases, No. 9201 Assumption, derived from [14, 15]
Rotavirus (severe) cases, No. 799 Assumption, derived from [14, 15]
Rotavirus case fatality ratea 4.29% Assumption, derived from [2, 11, 16]
Disability weight for DALY calculations
Rotavirus (nonsevere) cases 0.202 [17]
Rotavirus (severe) cases 0.281 [17]
Mean duration of illness, d
Rotavirus (nonsevere) cases 6 [6]
Rotavirus (severe) cases 6 [6]
Age distribution of disease cases and deaths
<3 mo 6.6% [6]
3–5 mo 19.4% [6]
6–8 mo 31.9% [6]
9–11 mo 19.8% [6]
12–23 mo 21.8% [6]
24–35 mo 0.5% [6]
36–47 mo 0% [6]
48–59 mo 0% [6]
Location of care seeking
Private pharmacy/clinic 15% Self-reported by this study cohort
Public/government primary health center 70% Self-reported by this study cohort
Public/government first-level hospital 10% Self-reported by this study cohort
Public/government referral-level hospital 5% Self-reported by this study cohort
Total coverage in first year following introduction
RV1 dose 1 90.2% [6]
RV1 dose 2 86.9% [6]
Coverage of dose 1 achieved by age in first year following introductionb
3 mo 75.8% [6]
6 mo 89.4% [6]
9 mo 89.9% [6]
12 mo 89.9% [6]
Coverage of dose 2 achieved by age in first year following introductionb
3 mo 32.2% [6]
6 mo 76.0% [6]
9 mo 84.5% [6]
12 mo 86.3% [6]
VE of 2 dosesc vs rotavirus (severe) cases
64% (95% CI, 24%–83%) [6]
VE of 2 dosesc vs rotavirus (nonsevere) cases
40% (95% CI, 30%–60%) Assumption, derived from [6]
Other vaccination impact assumptions
% decrease in dose effectiveness per year 47.5% (95% CI, 35.7%–59.4%) [18, 19]
Abbreviations: CI, confidence interval; DALY, disability-adjusted life-year; RV1, monovalent rotavirus vaccine; VE, vaccine effectiveness.
a Derived from diarrheal disease mortality estimate for Malawi [6]. In the absence of vaccination, this ratio is assumed to decline in each successive birth cohort in line with the general trend in
mortality among children aged <5 years. This is done by assuming that the fraction of deaths in the under-5 population caused by the disease remains fixed over time.
b Coverage projections over the period 2013–2033 were estimated by assuming rotavirus vaccine will achieve the same coverage and timeliness as diphtheria-tetanus-pertussis vaccine, and by
assuming a 5% annual decrease in the gap between final coverage in the cohort (coverage by age 24 mo) and a ceiling of 99.5% (RV1 dose 1) and 98.8% (RV1 dose 2).
c Effectiveness of single dose input at half that of 2 doses.
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(Table 4). These variables included cessation (rather than long-
term continuation) of Gavi support 10 or 15 years after introduc-
tion (but assuming unchanged vaccine cost), increased systems
costs, absence of waning immunity beyond the ﬁrst year of life,
lower vaccine effectiveness over time from rotavirus genotype
changes, lower case fatality rate, and lower costs of rotavirus
care. Details of speciﬁc scenarios are outlined in Table 4.
RESULTS
We recruited a total of 530 children with gastroenteritis, compris-
ing 118 outpatient and 282 children admitted at Queen Elizabeth
Central Hospital (urban setting), and 108 outpatient and 22 chil-
dren admitted at ChilumbaRuralHospital (rural setting) (Table 1).
Of these 530 children, 71 had rotavirus conﬁrmed by enzyme
immunoassay. Costs of illness did not differ by rotavirus status,
but from both a government healthcare provider perspective
and a household perspective, costs of inpatient care were greater,
as were costs of severe illness (Table 2).
Given model assumptions (Tables 1 and 2), we project that
over 20 years the rotavirus vaccine program will avert approxi-
mately 1 026 000 cases of rotavirus gastroenteritis, 78 000 inpa-
tient admissions, and 4300 deaths. Additionally, the rotavirus
vaccine program was projected to avert about 136 000 DALYs.
For the cohort born in 2015, this would translate to 54 000 cases
of rotavirus gastroenteritis averted and 281 fewer deaths before
the cohort reaches 5 years of age. Health and economic projec-
tions in absence and presence of vaccine are shown in Table 5.
The resultant cost-effectiveness is shown in Table 4. The cost of
the rotavirus vaccine program was calculated as just over $10.5
million. The total projected direct healthcare costs for gastroen-
teritis averted by vaccination were $8.0 million, and total society
costs averted were $9.2 million. Thus, government net cost is just
under $2.5 million and the societal net cost (the cost of the vac-
cine program minus the societal cost of illness that is averted by
the vaccination program) over the same period is $1.3 million.
The cost per DALY averted was $19 from a healthcare provider
perspective and $10 from a societal perspective, and the cost per
rotavirus case averted was $2 and $1, respectively. Thus, from
both the healthcare provider and societal perspectives, in Malawi
the rotavirus vaccine program is highly cost-effective.
Sensitivity Analyses
In all but 2 scenarios tested in sensitivity analyses, rotavirus vac-
cination remained highly cost-effective [4]. Although under an
assumption of no waning in immunity beyond the ﬁrst year of
life, the vaccine was cost-saving from a societal perspective, saving
Malawi >$1 million over 20 years (Table 4).
DISCUSSION
Rotavirus vaccine has been projected to be highly cost-effective
in the world’s poorest countries [27, 28], and its introduction is
now under way in many low-income countries with support
from Gavi. Studies in sub-Saharan Africa have recently estab-
lished this vaccine’s effectiveness and impact on population
Table 4. Discounted Cost-Effectiveness of Rotavirus Vaccine (20 Cohorts
Vaccinated During the Period 2014–2033)
Scenario
Government
Perspective
Societal
Perspective
Cost-effectiveness threshold
1 ×GDP per capita (2014)–WHO
threshold for “highly cost-
effective” [4]
$253 $253
3 ×GDP per capita (2014)–WHO
threshold for “cost-effective” [4]
$759 $759
Cost-effectiveness compared to no vaccine
Net cost of vaccine and related
program costs
$2 529 646 $1 308 333
Costs of vaccine program $10 528 367 $10 528 367
Health service costs avoided $7 998 721 $9 220 034
DALYs averted 136 290 136 290
US$ per DALY averted $19 $10
Univariate sensitivity analyses (in US$ per DALY averted)
Gavi withdraws support in 2023 $161 $152
Gavi withdraws support in 2028 $88 $79
Increased systems cost of 25% to
$0.53 per dose
$32 $23
No waning immunity in second year
of life
$2 Cost-savinga
Genotype changes lowering VE 15
percentage points
$160 $150
Lower cost of rotavirus care (lower
bound of 95% CI in Table 2)
$24 $18
Case fatality rate 2%.5% $32 $16
Costs and DALYs are discounted at 3% per year.
Abbreviations: CI, confidence interval; DALY, disability-adjusted life-year; GDP, gross
domestic product; VE, vaccine effectiveness; WHO, World Health Organization.
a This scenario is cost saving to a total of $1.29 million.
Table 5. Health and Economic Benefits (20 Cohorts Vaccinated During
the Period 2014–2033)
Cases and Costs No Vaccine With Vaccine Averted
Total rotavirus cases <5 y 5 303 276 4 277 313 1 025 922
Total severe cases <5 y 423 581 298 721 124 860
Total deaths <5 y 14 671 10 358 4313
DALY lost 464 990 328 700 136 290
YLD - DALY due to morbidity 2120 1730 380
YLL - DALY due to mortality 462 880 326 970 135 910
Total government health services
costs
$34 857 067 $26 860 346 $7 998 716
Total outpatient visit costs $22 765 954 $18 331 365 $4 434 584
Total inpatient admission costs $12 091 113 $8 528 981 $3 564 132
Total societal health services
costs
$39 572 280 $30 352 346 $9 220 034
Total outpatient visit costs $24 637 042 $19 819 510 $4 817 531
Total inpatient admission costs $14 935 238 $10 532 736 $4 402 503
Health benefits and costs are discounted at 3% per year.
Abbreviations: DALY, disability-adjusted life-year; YLD, years of life lost to disability; YLL,
years of life lost.
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burden of disease [6, 29]. These welcome beneﬁts, however,
must be judged relative to other potential uses of limited health
resources, and so establishing this vaccine’s cost-effectiveness
and budget impact is crucial. Available cost-effectiveness esti-
mates for Malawi, Uganda, and Kenya were based on assumed
rather than observed vaccine effectiveness and on modeled rath-
er than empirically observed costs of illness [7–9]. Additionally,
these studies did not include household-level costs in the esti-
mation of cost-effectiveness. In this comprehensive itemized
study of actual costs of medically attended gastroenteritis treat-
ment and vaccination, the cost to government of providing free
outpatient and especially inpatient care is substantial, and our
empirically observed costs are higher than previous projected
model-based estimates [9]. An intervention is generally consid-
ered highly cost-effective if it costs less than the per-capita GDP
(Table 4) [4]. Malawi has among the lowest per-capita GDP in
the world, yet even under such challenging economic condi-
tions we have shown that rotavirus vaccine is highly cost-
effective.
This study carefully and comprehensively collected actual costs
incurred by government in vaccine implementation. A study that
projected implementation costs and healthcare provider treatment
costs, but did not include household costs, found the program to
be relatively expensive for Malawi at $18.5 million over 5 years
[30]. Using similar methods but with actual expenditures, our
cost projection over 20 years was $10.5 million for the vaccination
program. Although it is possible we underestimated program
costs, ours were ministry-budgeted expenditures and not modeled
projections. Whereas the cost of the vaccination program is sub-
stantial, it is relatively small in relation to the $429 million in total
health expenditure in Malawi in 2013 [31]. Health expenditure in
Malawi has more than doubled over the last decade, so it is critical
that policy makers choose highly cost-effective health interven-
tions to maximize the impact of these investments.
We made every attempt to provide as accurate an estimate of
staff costs as was feasible. But we were unable to cost individual
minutes spent by staff in direct patient care, nor were we able to
include a patient complexity weighting [32]. However, consistent
with a previous study from a tertiary hospital in an afﬂuent area
of Johannesburg [33],we did not ﬁnd evidence of cost differential
by rotavirus status.We did ﬁnd higher costs for severe disease and
for inpatient care, but notably disease severity and admission sta-
tus were closely related (Table 2). Regardless of diarrhea etiology,
children are provided empiric treatment regimens in accordance
with a standard protocol based on WHO guidelines for dehydra-
tion [34], and admitted children have similar length of stay.
Costs for families were based on reported recall, and these
estimates could not be externally validated, so are subject to
recall biases. However, we did conduct home visits and could
conﬁrm other socioeconomic covariates by direct observation,
and interviewers had extensive training on appropriate ques-
tioning and follow-up prompting of responses to obtain and
conﬁrm information by parents. We suspect that the poorer
the household, the greater the risk of presenting with diarrheal
disease. This is an ascertainment bias of sorts, but also reﬂects
a reality that vaccination may be most important for the most
impoverished families, and is likely one of the more equitable
health interventions [35–37].We have estimated the household
costs of children attending care, but could not estimate costs to
those families too poor to afford access to care. We have, for
instance, recently shown that in the Karonga study site, distanc-
es to road and health facility are associated with delayed vaccine
uptake or nonreceipt of vaccines, and we speculate that the
same may be true for care seeking during illness. It is therefore
plausible that for the most destitute, costs of attending health-
care are prohibitive, and the very poorest children may be un-
able to attend care. This would bias our ﬁndings. We only
recruited children presenting for care, so have not included
costs to households of gastroenteritis episodes managed
at home. The latter could only be obtained through a large pop-
ulation cohort design, but the exclusion of such costs from
our analysis makes our estimate of cost-effectiveness more
conservative.
We used our observed population coverage rates and includ-
ed adjustment for effective coverage—that is, the coverage in
those at risk of disease relative to coverage in the entire birth
cohort (ie, overall coverage). We did not take into account
costs of possible secondary household cases linked to our
index patients, nor did we take into account indirect beneﬁts
of vaccination in averting secondary cases. If such indirect ef-
fects will occur in Malawi as they have elsewhere [33], this
would substantially increase the vaccine’s cost-effectiveness.
Should the burden of disease decline because of socioeconomic
improvements over time, then our model may overestimate
long-term cost-effectiveness. In sensitivity analyses we found
that even in many such circumstances the program remains
highly cost-effective. Forecasting the impact of future scenarios
on illness costs is conjectural at best, so our sensitivity analyses
should be interpreted with due caution. The purpose of these
analyses was not to predict future costs with precision, but to
test whether cost-effectiveness, broadly speaking, is maintained.
In this regard the outcome was consistently afﬁrmative. Over
time, countries will increasingly be required to bear a higher co-
payment for vaccine procurement, though cost of vaccine is
likely to decline over time. Although Malawi does not appear
to face an imminent increase in its copayment, even were this
to happen at current prices, cost-effectiveness would be main-
tained, perhaps even enhanced should future prices decline fur-
ther once additional products are marketed.
Although this study included primary healthcare, ﬁrst-refer-
ral-level, and tertiary-level facilities in urban and rural settings
and included inpatients and outpatients, caution is warranted in
extrapolating our ﬁndings to other settings, particularly those in
which vaccine effectiveness has not been evaluated, or whose
S226 • CID 2016:62 (Suppl 2) • Bar-Zeev et al
healthcare systems differ substantially fromMalawi. In addition,
the very presence of our longstanding research activities at our
recruitment sites may reduce applicability to other government
clinics where research and, by implication, an emphasis on
good quality clinical care are enhanced. Malawi’s population uti-
lization of primary and subsequent referral-level care was uncer-
tain; thus, we assumed proportions based on healthcare utilization
reported by our cohort. We ran our models with differing but
plausible distributions, and this did not dramatically affect cost-
effectiveness estimates. We therefore believe it is likely that in
many resource-limited settings our ﬁndings have applicability,
but clearly local health planners should be mindful of their own
settings when considering the relevance of our ﬁndings. Model-
based expectations of cost-effectiveness have been reported from
Southeast Asia, where the vaccine is yet to be introduced [28].
The Malawian economy underwent a period of substantial
instability in the wake of the devaluation of the kwacha in
2012. This ushered in inﬂation and marked increases in costs
of goods and services. Inﬂation had stabilized by the time we
embarked on the bulk of our recruitment, but the uncertain
economic climate persists. Such turbulence is difﬁcult to adjust
for in analysis, but is all too common in low-income countries.
Indeed, such instabilities are often associated with increased ill-
ness, thereby strengthening further the argument for introduc-
ing and maintaining vaccine programs that are effective and
cost-effective even in the short run.
In conclusion, gastroenteritis episodes represent a substantial
economic burden to government and to families.We foundmono-
valent rotavirus vaccine to be highly cost-effective in Malawi, even
under challenging possible future scenarios. Together with the
demonstrated impact of monovalent rotavirus vaccine in reducing
population hospitalization burden, the additional cost savings
afforded by this vaccine make a strong argument for the wide-
spread introduction in other low-income, high-burden settings.
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